RT Journal Article
SR Electronic
T1 Simultaneous Monitoring of Disease and Microbe Dynamics Through Plasma DNA Sequencing in Pediatric Patients with Acute Lymphoblastic Leukemia
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.03.30.21253149
DO 10.1101/2021.03.30.21253149
A1 Valentin Barsan
A1 Yuntao Xia
A1 David Klein
A1 Veronica Gonzalez-Pena
A1 Sarah Youssef
A1 Yuki Inaba
A1 Ousman Mahmud
A1 Sivaraman Natarajan
A1 Vibhu Agarwal
A1 Yakun Pang
A1 Robert Autry
A1 Ching-Hon Pui
A1 Hiroto Inaba
A1 William Evans
A1 Charles Gawad
YR 2021
UL http://medrxiv.org/content/early/2021/04/04/2021.03.30.21253149.abstract
AB Treatment of acute lymphoblastic leukemia (ALL) necessitates continuous risk assessment of leukemic disease burden as well as infections that arise in the setting of immunosuppression and myelosuppression. This study was performed to assess the feasibility of a hybrid capture NGS panel to longitudinally measure molecular leukemic disease clearance and microbial species abundance in 20 pediatric patients with ALL throughout induction chemotherapy. This proof-of-concept helps establish a technical and conceptual framework that we anticipate will be expanded and applied to additional patients with leukemias, as well as extended to additional cancers. Molecular monitoring can help to accelerate the attainment of insights into the temporal biology of host-microbe-leukemia interactions, including how those changes correlate with and alter anticancer therapy efficacy. We also anticipate fewer invasive bone marrow aspirations or biopsies will be required as these methods improve with standardization and are validated for clinical use.Key PointsA custom-designed hybridization capture next generation sequencing (NGS) panel noninvasively and quantitatively measures leukemic disease burden and microbial species abundance through serial peripheral blood draws throughout induction chemotherapy.Sequencing of circulating tumor DNA (ctDNA) alongside microbial cell free DNA (mcfDNA) in the same sample reveals the effectiveness of chemotherapy alongside the immunosuppressive consequences of cytotoxic therapy.Efforts to incorporate ctDNA and mcfDNA NGS monitoring in higher risk patient populations have the potential to uncover mechanisms of response, resistance, and infectious complications that correlate with patient outcomes.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT03117751Funding StatementWe would like to acknowledge Joshua Stokes from St. Jude Biomedical Communications for contributing to the figure generation. V.B. is an Anne T. and Robert M. Bass Endowed Fellow, supported by the Stanford Child Health Research Institute. C.G. is supported by a Career Award for Medical Scientists from the Burroughs Welcome Fund, NIH Directors New Innovator Award (1DP2CA239145-01), and the Chan Zuckerberg Biohub. This work was also supported by St. Jude Cancer Center Developmental Funds (2P30CA021765-40), the Eleftheria Foundation, and ALSAC.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The protocol was reviewed and approved by the St. Jude and Stanford Institutional Review Boards. Ages / sex of patients are necessarily enumerated in table 1 as specific age and sex are prognostically meaningful information for this patient cohort and otherwise NOT identifiable information for any particular patient. Table 1 is thus fully compliant with guidance at https://www.hhs.gov/hipaa/for-professionals/privacy/special-topics/de-identification/index.html St. Jude IRB Contact: Hiroto Inaba, MD, PhD866-278-5833 referralinfo{at}stjude.org and Stanford IRB contact: Norman J. Lacayo, MD 650-723-5535 lacayon{at}stanford.edu All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe sequencing data from this study will be deposited into the Short Read Archive prior to publication.